Melphalan

Generic Name: Melphalan

Brand Names: Alkeran, Evomela, Phelinun, Pepaxti

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈Cl_₂N_₂O_₂

CAS Number: 148-82-3

Unique Ingredient Identifier: Q41OR9510P

Background: Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication: Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions: Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

Phase 2

Conditions: Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-04-18

Last Posted Date: 2014-01-06

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 10

Registration Number: NCT00003163

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2003-04-16

Last Posted Date: 2012-04-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 61

Registration Number: NCT00002945

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy in Treating Patients With Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: Filgrastim (G-CSF)
Biological: Bleomycin Sulfate (BLM)
Biological: Recombinant Interferon Alfa
Drug: Carmustine
Drug: Cytarabine (ARA-C)
Drug: Cisplatin (CDDP)
Drug: Etoposide (VP-16)
Drug: Cyclophosphamide
Drug: Ifosfamide
Drug: Idarubicin
Drug: Melphalan
Drug: Leucovorin Calcium
Drug: mitoxantrone hydrochloride (DHAD)
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Methylprednisolone
Drug: Vincristine Sulfate
Radiation: Radiation Therapy

First Posted Date: 2003-04-16

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 116

Registration Number: NCT00002835

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma

Phase 3

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-04-10

Last Posted Date: 2013-12-19

Lead Sponsor: Medical Research Council

Target Recruit Count: 1000

Registration Number: NCT00002653

Locations: 🇬🇧
MRC Myelomatosis Trials Office, Birmingham, England, United Kingdom

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: Carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: peripheral blood stem cell transplantation
Radiation: yttrium Y 90 ibritumomab tiuxetan

First Posted Date: 2003-04-09

Last Posted Date: 2012-06-01

Lead Sponsor: Northwestern University

Target Recruit Count: 44

Registration Number: NCT00058292

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic-Myeloproliferative Diseases

First Posted Date: 2003-03-07

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00055653

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
North Shore University Hospital, Manhasset, New York, United States

and more 22 locations

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma

Interventions: Drug: fludarabine phosphate
Drug: melphalan
Radiation: total-body irradiation
Drug: mycophenolate mofetil
Drug: cyclosporine
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2003-02-06

Last Posted Date: 2017-10-16

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00054353

Locations: 🇮🇹
University of Torino, Torino, Italy
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cisplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: isotretinoin
Drug: melphalan
Drug: topotecan hydrochloride
Drug: vincristine sulfate
Procedure: autologous bone marrow transplantation
Procedure: bone marrow ablation with stem cell support
Procedure: conventional surgery
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-17

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 495

Registration Number: NCT00004188

Locations: 🇺🇸
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 93 locations

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Phase 2

Completed

Conditions: Graft Versus Host Disease
Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00014469

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002982

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy